Multiple Roles of Chemokine (C-C Motif) Ligand 2 in Promoting Prostate Cancer Growth
Open Access
- 16 March 2010
- journal article
- review article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 102 (8), 522-528
- https://doi.org/10.1093/jnci/djq044
Abstract
Prostate cancer continues to be the most common nonskin cancer diagnosed and the second leading cause of cancer death in men in the United States. Prostate cancer that has metastasized to bone remains incurable. The interactions between prostate cancer cells and the various cells of the host microenvironment result in enhanced growth of tumor cells and activation of host cells that together culminate in osteoblastic bone metastases. These dynamic tumor–host interactions are mediated by cancer and host-produced cytokines and chemokines. Among them, chemokine (C-C motif) ligand 2 (CCL2) has been identified as a prominent modulator of metastatic growth in the bone microenvironment. CCL2 is produced by bone marrow osteoblasts, endothelial cells, stromal cells, and prostate cancer cells. It has been demonstrated to modulate tumor-associated macrophage migration and promote osteoclast maturation. In addition, CCL2 functions through binding to its receptor CCR2 to induce prostate cell proliferation, migration, and invasion in both autocrine and paracrine manners. CCL2 protects prostate cancer cells from autophagic death by activating survivin through a PI3K/AKT (phosphatidylinositol 3-kinase/protein kinase B)–dependent mechanism. Inhibition of CCL2 substantially decreases macrophage infiltration, decreases osteoclast function, and inhibits prostate cancer growth in bone in preclinical animal models. The multiple roles of CCL2 in the tumor microenvironment make it an attractive therapeutic target in metastatic prostate cancer as well as in other cancers.This publication has 84 references indexed in Scilit:
- A Destructive Cascade Mediated by CCL2 Facilitates Prostate Cancer Growth in BoneCancer Research, 2009
- Prostate cancer promotes CD11b positive cells to differentiate into osteoclastsJournal of Cellular Biochemistry, 2009
- CCL2 Protects Prostate Cancer PC3 Cells from Autophagic Death via Phosphatidylinositol 3-Kinase/AKT-dependent Survivin Up-regulationOnline Journal of Public Health Informatics, 2008
- The evolving biology and treatment of prostate cancerJCI Insight, 2007
- Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastasesBMC Cancer, 2007
- Chemokine (C-C Motif) Ligand 2 Mediates the Prometastatic Effect of Dysadherin in Human Breast Cancer CellsCancer Research, 2006
- CCL2 is a Potent Regulator of Prostate Cancer Cell Migration and ProliferationNeoplasia, 2006
- Macrophage level is not affected by monocyte chemotactic protein-1 in invasive ductal breast carcinomaZeitschrift für Krebsforschung und Klinische Onkologie, 2005
- Transendothelial Migration of Myeloma Cells Is Increased by Tumor Necrosis Factor (TNF)-α via TNF Receptor 2 and Autocrine Up-Regulation of MCP-1Clinical Cancer Research, 2004
- Monocyte chemoattractant protein-1 serum levels in ovarian cancer patientsBritish Journal of Cancer, 1999